La chaîne d'options affiche les données clés des options sur actions de Aptevo Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Aptevo Therapeutics..

Aptevo Therapeutics (NASDAQ:APVO) Stock, Chaîne d'Options

Aptevo Therapeutics

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Aptevo Therapeutics Inc

News

Press Releases

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

AIHS

APVO

CHEK

NSRGY

PRSO

TOMZ

TURB

Abpro Hldgs

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioCardia

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

BioVie

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Curis

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Edesa Biotech

enGene Holdings

FibroBiologics

Geovax Labs

Immuron Limited - American Depositary Shares

Immuron

Longeveron

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lunai Bioworks

Lisata Therapeutics

Moleculin Biotech

OSR Holdings

BiomX

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

Synlogic

Tharimmune

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty

Roth MKM

Comments

Aptevo Therapeutics

Aptevo Therapeutics (APVO) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL